MCID: NRG002
MIFTS: 50

Neurogenic Bladder malady

Categories: Neuronal diseases, Nephrological diseases

Aliases & Classifications for Neurogenic Bladder

Aliases & Descriptions for Neurogenic Bladder:

Name: Neurogenic Bladder 12 29 14
Neurogenic Dysfunction of the Urinary Bladder 12
Neurogenic Urinary Bladder Disorder 12
Urinary Bladder, Neurogenic 42
Neurogenic Urinary Bladder 69
Neuropathic Bladder 12
Bladder Neurogenic 52

Classifications:



External Ids:

Disease Ontology 12 DOID:12143
ICD9CM 35 596.54
MeSH 42 D001750
NCIt 47 C79696
UMLS 69 C0005697

Summaries for Neurogenic Bladder

MalaCards based summary : Neurogenic Bladder, also known as neurogenic dysfunction of the urinary bladder, is related to brain injury and hinman syndrome, and has symptoms including dysuria, meningism and pain. An important gene associated with Neurogenic Bladder is HPSE2 (Heparanase 2 (Inactive)), and among its related pathways/superpathways are Calcium signaling pathway and Arf6 trafficking events. The drugs Acetylcholine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, testes and kidney, and related phenotypes are cardiovascular system and nervous system

Wikipedia : 71 Neurogenic bladder dysfunction, sometimes simply referred to as neurogenic bladder, is a dysfunction of... more...

Related Diseases for Neurogenic Bladder

Diseases related to Neurogenic Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Related Disease Score Top Affiliating Genes
1 brain injury 29.2 P2RX2 UPK3A
2 hinman syndrome 11.4
3 urofacial syndrome 1 11.1
4 polyglucosan body disease, adult form 11.0
5 adult polyglucosan body disease 11.0
6 lethal congenital contractural syndrome 2 10.9
7 lethal congenital contractural syndrome 3 10.9
8 spinal cord injury 10.4
9 vesicoureteral reflux 10.2
10 myelomeningocele 10.2
11 bacteriuria 10.2
12 bladder disease 10.1
13 urethritis 10.1
14 prostatitis 10.0
15 cystitis 9.9
16 cone-rod dystrophy 15 9.9 HPSE2 LRIG2
17 herpes zoster 9.9
18 cerebritis 9.9
19 spasticity 9.8
20 cerebral palsy 9.8
21 cervicitis 9.8
22 lymphocytic choriomeningitis 9.8 MEOX2 P2RX1 P2RX2
23 fuchs' heterochromic uveitis 9.8 KIDINS220 UPK3A
24 bladder neck obstruction 9.7
25 systemic lupus erythematosus 9.7
26 interstitial cystitis 9.7
27 kidney disease 9.7
28 prostatic hypertrophy 9.7
29 pyelonephritis 9.7
30 perinephritis 9.7
31 lupus erythematosus 9.7
32 lambert-eaton myasthenic syndrome 9.6
33 spinal cord ependymoma 9.6
34 horseshoe kidney 9.6
35 posterior urethral valves 9.6
36 latex allergy 9.6
37 paraplegia 9.6
38 spastic paraparesis 9.6
39 multiple myeloma 9.6
40 spina bifida occulta 9.6
41 down syndrome 9.6
42 acquired immunodeficiency syndrome 9.6
43 central cord syndrome 9.6
44 endocarditis 9.6
45 pyuria 9.6
46 spondylitis 9.6
47 leukodystrophy 9.6
48 neuroleptic malignant syndrome 9.6
49 radiation cystitis 9.6
50 urachal diverticulum 9.6

Comorbidity relations with Neurogenic Bladder via Phenotypic Disease Network (PDN): (show all 30)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Hypertension, Essential
Hypothyroidism Ischemic Heart Disease
Multiple Sclerosis, Disease Progression, Modifier of Osteoporosis
Paralytic Ileus Paraplegia
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Prostatic Hypertrophy Protein-Energy Malnutrition
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia Urethral Stricture

Graphical network of the top 20 diseases related to Neurogenic Bladder:



Diseases related to Neurogenic Bladder

Symptoms & Phenotypes for Neurogenic Bladder

UMLS symptoms related to Neurogenic Bladder:


dysuria, meningism, pain, paresis, reflex, abnormal, seizures, vertigo, neurobehavioral manifestations, neuromuscular manifestations

MGI Mouse Phenotypes related to Neurogenic Bladder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.5 CHRM2 GBE1 KIDINS220 MEOX2 P2RX1 P2RX2
2 nervous system MP:0003631 9.17 GBE1 KIDINS220 LRIG2 MEOX2 P2RX2 PIP5K1C

Drugs & Therapeutics for Neurogenic Bladder

Drugs for Neurogenic Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Sulfamethoxazole Approved Phase 4,Phase 1,Phase 2 723-46-6 5329
4
Oxybutynin Approved, Investigational Phase 4,Phase 3 5633-20-5 4634
5
Trimethoprim Approved, Vet_approved Phase 4,Phase 1,Phase 2 738-70-5 5578
6
Silodosin Approved Phase 4 160970-54-7
7
Fosfomycin Approved Phase 4 23155-02-4 446987
8
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
9
Darifenacin Approved, Investigational Phase 4,Phase 2 133099-04-4 444031
10
Cefixime Approved Phase 4 79350-37-1 54362 5362065
11
Trospium Approved Phase 4,Phase 1 10405-02-4, 47608-32-2 5596 5284631
12
Morphine Approved, Investigational Phase 4 57-27-2 5288826
13 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
16 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Adrenergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
18 Neuromuscular Agents Phase 4,Phase 3,Phase 2
19 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
20 Adrenergic alpha-Antagonists Phase 4,Phase 2,Phase 3,Phase 1
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Anesthetics Phase 4,Phase 3
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
25 abobotulinumtoxinA Phase 4,Phase 3,Phase 2
26 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
27 onabotulinumtoxinA Phase 4,Phase 3,Phase 2
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
31 Antitubercular Agents Phase 4,Phase 1,Phase 2
32 Botulinum Toxins Phase 4,Phase 3,Phase 2
33 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2
34 Clavulanic Acid Phase 4
35 Solifenacin succinate Phase 4,Phase 3,Phase 1 242478-38-2
36 Parasympatholytics Phase 4,Phase 3,Phase 1
37 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
38 Anticonvulsants Phase 4,Phase 1
39 Mandelic Acids Phase 4,Phase 3
40 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Bromides Phase 4,Phase 1
42 Central Nervous System Depressants Phase 4,Phase 3
43 Analgesics Phase 4
44 Narcotics Phase 4
45 Analgesics, Opioid Phase 4
46 Belladonna Nutraceutical Phase 4
47
Tamsulosin Approved, Investigational Phase 2, Phase 3,Phase 1 106133-20-4 129211
48
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
49
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
50
Ofloxacin Approved Phase 3 82419-36-1 4583

Interventional clinical trials:

(show top 50) (show all 131)
id Name Status NCT ID Phase
1 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4
2 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4
3 Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome Unknown status NCT01157507 Phase 4
4 Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder Completed NCT01228370 Phase 4
5 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease Completed NCT01421719 Phase 4
6 Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4
7 Quality of Life Intermittent Catheter Study Completed NCT01523743 Phase 4
8 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4
9 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Completed NCT00224029 Phase 4
10 Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome Completed NCT00277563 Phase 4
11 Onabotulinumtoxina Intradetrusorial Injections and NGF Expression Completed NCT01629433 Phase 4
12 A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients Completed NCT02601287 Phase 4
13 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed NCT00800462 Phase 4
14 Prevention of Bladder Dysfunction in Acute Spinal Cord Injury Recruiting NCT01698138 Phase 4
15 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository Enrolling by invitation NCT02600715 Phase 4
16 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder Suspended NCT01192568 Phase 4
17 Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder Terminated NCT01023269 Phase 4
18 Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity Terminated NCT01796548 Phase 4
19 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3
20 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3
21 Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Completed NCT01716624 Phase 3
22 Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder Completed NCT00796614 Phase 2, Phase 3
23 Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction Completed NCT00549939 Phase 3
24 Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Completed NCT00629720 Phase 3
25 Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology Completed NCT00576823 Phase 3
26 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed NCT01600716 Phase 3
27 Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity Completed NCT01530620 Phase 3
28 Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Completed NCT01472263 Phase 3
29 Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients Completed NCT00280592 Phase 3
30 A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections Completed NCT00258089 Phase 3
31 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Completed NCT00461292 Phase 3
32 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Completed NCT00311376 Phase 3
33 A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) Completed NCT01981954 Phase 3
34 Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity Completed NCT01091727 Phase 3
35 A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Patients 5 to 18 Years of Age With Neurogenic Detrusor Overactivity Completed NCT01565694 Phase 3
36 A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition Recruiting NCT01557244 Phase 3
37 Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity. Recruiting NCT02501928 Phase 3
38 Transcutaneous Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction Recruiting NCT02859844 Phase 3
39 Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity Recruiting NCT02849418 Phase 3
40 OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER Recruiting NCT01050114 Phase 3
41 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 Recruiting NCT02660359 Phase 3
42 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 Recruiting NCT02660138 Phase 3
43 Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses Recruiting NCT02816151 Phase 3
44 Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity Recruiting NCT02751931 Phase 3
45 Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients Enrolling by invitation NCT02044510 Phase 2, Phase 3
46 A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB) Enrolling by invitation NCT02786407 Phase 3
47 Antiseptic-coated Intermittent Urinary Catheter Not yet recruiting NCT02697162 Phase 2, Phase 3
48 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Terminated NCT00439140 Phase 3
49 Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder Unknown status NCT02044965 Phase 1, Phase 2
50 Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization Unknown status NCT01305681 Phase 1, Phase 2

Search NIH Clinical Center for Neurogenic Bladder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: urinary bladder, neurogenic

Genetic Tests for Neurogenic Bladder

Genetic tests related to Neurogenic Bladder:

id Genetic test Affiliating Genes
1 Neurogenic Bladder 29

Anatomical Context for Neurogenic Bladder

MalaCards organs/tissues related to Neurogenic Bladder:

39
Spinal Cord, Testes, Kidney, Prostate, Colon, Brain, T Cells

Publications for Neurogenic Bladder

Articles related to Neurogenic Bladder:

(show top 50) (show all 614)
id Title Authors Year
1
Applicability of botulinum toxin type A in paediatric neurogenic bladder management. ( 27748667 )
2017
2
Correlating spinal cord injuries with neurogenic bladder pathophysiology. ( 28090756 )
2017
3
A framework for transitioning patients from pediatric to adult health settings for patients with neurogenic bladder. ( 27276694 )
2016
4
The Management of the Pediatric Neurogenic Bladder. ( 27610207 )
2016
5
Button Cystostomy: Is it really a Safe and Effective Therapeutic Option in Paediatric Patients with Neurogenic Bladder? ( 27693876 )
2016
6
Augmentation enterocystoplasty without reimplantation for patients with neurogenic bladder and vesicoureteral reflux. ( 27377846 )
2016
7
Predictive Factors for Intermittent Self-catheterization in German and Brazilian Individuals With Spina Bifida and Neurogenic Bladder Dysfunction. ( 27556346 )
2016
8
Effectiveness of intermittent urinary catheterization in patients with neurogenic bladder: a systematic review protocol. ( 28009670 )
2016
9
Sacral nerve stimulation for neurogenic bladder. ( 26960284 )
2016
10
Retrograde pyelonephritis and lumbar spondylitis as a result of Salmonella typhi in a typeA 2 diabetes patient with neurogenic bladder. ( 27330732 )
2016
11
Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson's disease. ( 27596481 )
2016
12
Management of neurogenic bladder in patients with multiple sclerosis. ( 27030526 )
2016
13
Bladder wall thickness in the assessment of neurogenic bladder: a translational discussion of current clinical applications. ( 26889485 )
2016
14
Retrospective clinic and urodynamic study in the neurogenic bladder dysfunction caused by human T cell lymphotrophic virus type 1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). ( 26756420 )
2016
15
Localized inhibition of P2X7R at the spinal cord injury site improves neurogenic bladder dysfunction by decreasing urothelial P2X3R expression in rats. ( 28039004 )
2016
16
Remarkable Points for Urodynamic Studies in Neurogenic Bladder Management. ( 27461447 )
2016
17
Chronic Kidney Disease in Neurogenic Bladder. ( 28035730 )
2016
18
Bulbocavernosus Reflex Test for Diagnosis of Pudendal Nerve Injury in Female Patients with Diabetic Neurogenic Bladder. ( 28053822 )
2016
19
Prospective evaluation of antibiotic treatment for urological procedure in patients presenting with neurogenic bladder. ( 27241225 )
2016
20
Identifying and classifying quality of life tools for neurogenic bladder function after spinal cord injury: A systematic review. ( 27734771 )
2016
21
Congenital causes of neurogenic bladder and the transition to adult care. ( 26904411 )
2016
22
Patient reported outcome measures in neurogenic bladder. ( 26904409 )
2016
23
Sacral agenesis and neurogenic bladder: Long-term outcomes of bladder and kidney function. ( 26897325 )
2016
24
Combinational effects of muscarinic receptor inhibition and I^3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury. ( 27367752 )
2016
25
Retroaortic Variant of Reverse Horseshoe Kidney With Butterfly Vertebrae Presenting as Neurogenic Bladder. ( 27282812 )
2016
26
Augmentation cystoplasty in neurogenic bladder. ( 27617312 )
2016
27
Conditional Electrical Stimulation in Animal and Human Models for Neurogenic Bladder: Working Toward a Neuroprosthesis. ( 27920880 )
2016
28
Not all neurogenic bladders are the same: a proposal for a new neurogenic bladder classification system. ( 26904408 )
2016
29
Complications of untreated and ineffectively treated neurogenic bladder dysfunctions in children: our own practical classification. ( 27097940 )
2016
30
The Factors That Affect Improvement of Neurogenic Bladder by Severe Lumbar Disc Herniation in Operation. ( 27799991 )
2016
31
Neurogenic Bladder Repair Using Autologous Mesenchymal Stem Cells. ( 27656308 )
2016
32
Re: Screening for Depression and Anxiety in Childhood Neurogenic Bladder Dysfunction. ( 26853031 )
2016
33
Role of gabapentin and anticholinergics in management of neurogenic bladder after repair of spina bifida - a randomized controlled study. ( 27680597 )
2016
34
Typical Value Ranges and Typical Signal Patterns in the Initial Cough in Patients With Neurogenic Bladder: Quality Control in Urodynamic Studies. ( 27706014 )
2016
35
Do patients with neurogenic bladder treated with clean intermittentcatheterization need antibacterial prophylaxis? ( 27513418 )
2016
36
An Evaluation of the Efficacy of Selective Alpha-Blockers in the Treatment of Children with Neurogenic Bladder Dysfunction-Preliminary Findings. ( 26999168 )
2016
37
Neuromodulation in neurogenic bladder. ( 26904417 )
2016
38
A 4-year prospective urological assessment of in utero Myelomeningocele repair: Does gestational age at birth play a role at later neurogenic bladder pattern? ( 27988193 )
2016
39
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults. ( 26904410 )
2016
40
Urinary tract infection in the neurogenic bladder. ( 26904414 )
2016
41
Medical management of neurogenic bladder with oral therapy. ( 26904412 )
2016
42
Management options for sphincteric deficiency in adults with neurogenic bladder. ( 26904420 )
2016
43
Barriers to transition in young adults with neurogenic bladder. ( 27270070 )
2016
44
The role of botulinum toxin A in treating neurogenic bladder. ( 26904413 )
2016
45
Barriers to transition in young adults with neurogenic bladder. ( 27524424 )
2016
46
Spinal extradural arachnoid cyst: A rare cause of neurogenic bladder. ( 27365974 )
2016
47
TAU focused issue on adult management of neurogenic bladder. ( 26904406 )
2016
48
Importance of Neurogenic Bladder as a Cause of Drainage Failure. ( 27006442 )
2016
49
Botulinum Toxin to Treat Neurogenic Bladder. ( 26866490 )
2016
50
Comparison of different antibiotic protocols for asymptomatic bacteriuria in patients with neurogenic bladder treated with botulinum toxin A. ( 27765580 )
2016

Variations for Neurogenic Bladder

ClinVar genetic disease variations for Neurogenic Bladder:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 EBF3 NM_001005463.2(EBF3): c.512G> A (p.Gly171Asp) single nucleotide variant Pathogenic rs1057519437 GRCh37 Chromosome 10, 131755564: 131755564

Expression for Neurogenic Bladder

Search GEO for disease gene expression data for Neurogenic Bladder.

Pathways for Neurogenic Bladder

Pathways related to Neurogenic Bladder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.07 CHRM2 P2RX1 P2RX2
2 10.6 CHRM2 PIP5K1C

GO Terms for Neurogenic Bladder

Cellular components related to Neurogenic Bladder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 8.96 P2RX1 P2RX2
2 integral component of nuclear inner membrane GO:0005639 8.62 P2RX1 P2RX2

Biological processes related to Neurogenic Bladder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 excitatory postsynaptic potential GO:0060079 9.26 P2RX1 P2RX2
2 response to ATP GO:0033198 9.16 P2RX1 P2RX2
3 regulation of smooth muscle contraction GO:0006940 8.96 CHRM2 P2RX1
4 purinergic nucleotide receptor signaling pathway GO:0035590 8.62 P2RX1 P2RX2

Molecular functions related to Neurogenic Bladder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular ATP-gated cation channel activity GO:0004931 8.96 P2RX1 P2RX2
2 purinergic nucleotide receptor activity GO:0001614 8.62 P2RX1 P2RX2

Sources for Neurogenic Bladder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....